Meeting Report
Advancing Precision-Targeted Treatment for Patients With Metastatic Non–Small Cell Lung Cancer
Presented by Tajuana Bradley,(1) MSN, APRN-BC, and Beth Sandy,(2) MSN, CRNP, FAPO
From (1)Georgia Cancer Specialists, affiliated with Northside Hospital Cancer Institute, Lawrenceville, Georgia; (2)Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
Presenters’ disclosures of conflicts of interest are found at the end of this article.
J Adv Pract Oncol 2024;15(3):191–195 |
https://doi.org/10.6004/jadpro.2024.15.3.7 |
© 2024 BroadcastMed LLC
ABSTRACT
At JADPRO Live 2023, presenters discussed the implications of biomarker testing, pivotal clinical trials leading to recent FDA approvals, and evidence-based best practices for monitoring and managing adverse events associated with molecular targeted and combination therapies for patients with metastatic non–small cell lung cancer.
For access to the full length article, please
sign in.
